Sevoflurane Mediates LINC00339/miR‐671‐5p/PSMB2 Axis to Improve Cardiomyocytes Against Hypoxia/Reoxygenation Injury
Journal of Biochemical and Molecular Toxicology · 2025-04 · 39 (4)
DOI: 10.1002/jbt.70234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 27.03.2025. Verfasst von Juan Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Third Ward of Cardiology Department, Tengzhou Central People's Hospital, Tengzhou, China. Hauptthemen laut MEDLINE: MicroRNAs, Myocytes, Cardiac, Sevoflurane, RNA, Long Noncoding. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Ischemia/reperfusion (I/R) causes a deterioration in heart function, leading to myocardial infarction. It is aimed at investigating the protective mechanism of sevoflurane (Sevo) on cardiomyocytes by constructing a cellular model of hypoxic/reoxygenation (H/R) in this study.[Human hybrid] epithelioid cells (AC16) were induced by H/R to establish a model of myocardial I/R injury and Sevo postconditioning. The expression of long intergenic non‐protein coding RNA 339 (LINC00339), microRNA‐671‐5p (miR‐671‐5p) and proteasome 20S subunit beta 2 (PSMB2) was detected by quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR). Viability and apoptosis of AC16 cells were detected by cell counting kit‐8 (CCK‐8) assay and flow cytometry, respectively. The levels of interleukin‐6 (IL‐6), IL‐10, tumor necrosis factor‐a (TNF‐a), reactive oxygen species (ROS), malondialdehyde (MDA), glutathione peroxidase (GSH‐Px) and superoxide dismutase (SOD), were detected. LINC00339 expression was upregulated in H/R cardiomyocytes relative to the Control group, whereas Sevo decreased LINC00339 expression in H/R cardiomyocytes. The viability of AC16 cells were increased, and apoptosis, oxidative stress, and inflammatory responses decreased in the Sevo postconditioning group relative to the H/R group, but the protective effect of Sevo on H/R cardiomyocytes was partially reversed by LINC00339 overexpression. LINC00339 negatively regulated miR‐671‐5p, and miR‐671‐5p upregulation could alleviate the damage of LINC00339 on H/R cardiomyocytes. PSMB2, a downstream target gene of miR‐671‐5p, could inhibit the protective effect of Sevo on H/R cardiomyocytes. Sevo postconditioning exerts a protective effect in H/R‐induced cardiomyocyte injury, which may be achieved by interfering with LINC00339/miR‐671‐5p/PSMB2 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Third Ward of Cardiology Department, Tengzhou Central People's Hospital, Tengzhou, China.
- Department of Cardiovascular Medicine, Nanchong Central Hospital, The Second Clinical Medical College of North Sichuan Medical College, Nanchong, China.
- Department of Anesthesiology, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Department of Pain Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing, China.
- Department of Anesthesiology, The Second Xiangya Hospital, Central South University, Changsha, China.
Zitieren
APA
Li, J., Mou, C., Yuan, Y., Wang, L., & Wu, C. (2025). Sevoflurane Mediates LINC00339/miR‐671‐5p/PSMB2 Axis to Improve Cardiomyocytes Against Hypoxia/Reoxygenation Injury. Journal of Biochemical and Molecular Toxicology, 39(4). https://doi.org/10.1002/jbt.70234
Vancouver
Li J, Mou C, Yuan Y, Wang L, Wu C. Sevoflurane Mediates LINC00339/miR‐671‐5p/PSMB2 Axis to Improve Cardiomyocytes Against Hypoxia/Reoxygenation Injury. Journal of Biochemical and Molecular Toxicology. 2025;39(4). doi:10.1002/jbt.70234
BibTeX
@article{Li2025,
author = {Li, Juan and Mou, Chuan and Yuan, Yawei and Wang, Long and Wu, Caihong},
title = {Sevoflurane Mediates LINC00339/miR‐671‐5p/PSMB2 Axis to Improve Cardiomyocytes Against Hypoxia/Reoxygenation Injury},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
volume = {39},
number = {4},
doi = {10.1002/jbt.70234}
}
EUVIMED